Mårten Segelmark

16.6k total citations · 3 hit papers
185 papers, 8.1k citations indexed

About

Mårten Segelmark is a scholar working on Pulmonary and Respiratory Medicine, Nephrology and Genetics. According to data from OpenAlex, Mårten Segelmark has authored 185 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Pulmonary and Respiratory Medicine, 56 papers in Nephrology and 49 papers in Genetics. Recurrent topics in Mårten Segelmark's work include Vasculitis and related conditions (114 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (47 papers) and Renal Diseases and Glomerulopathies (40 papers). Mårten Segelmark is often cited by papers focused on Vasculitis and related conditions (114 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (47 papers) and Renal Diseases and Glomerulopathies (40 papers). Mårten Segelmark collaborates with scholars based in Sweden, United Kingdom and United States. Mårten Segelmark's co-authors include Thomas Hellmark, Jörgen Wieslander, Kerstin Westman, Thomas Häuser, Aladdin J Mohammad, David Jayne, Vladimı́r Tesař, Alfred Mahr, Daniel Söderberg and Jan Willem Cohen Tervaert and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and SHILAP Revista de lepidopterología.

In The Last Decade

Mårten Segelmark

176 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis

2010 1.1k citations Rachel Jones, Jan Willem Cohen Tervaert et al. profile →
Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies

2006 913 citations Thomas Häuser, Mårten Segelmark et al. Annals of the Rheumatic Diseases profile →
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis

2017 420 citations David Jayne, Annette Bruchfeld et al. Journal of the American Society of Nephrology profile →

Peers

Countries citing papers authored by Mårten Segelmark

Since Specialization

Citations

This map shows the geographic impact of Mårten Segelmark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mårten Segelmark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mårten Segelmark more than expected).

Fields of papers citing papers by Mårten Segelmark

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mårten Segelmark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mårten Segelmark. The network helps show where Mårten Segelmark may publish in the future.

Co-authorship network of co-authors of Mårten Segelmark

This figure shows the co-authorship network connecting the top 25 collaborators of Mårten Segelmark. A scholar is included among the top collaborators of Mårten Segelmark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mårten Segelmark. Mårten Segelmark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Epidemiology and clinical characteristics of biopsy-confirmed adult-onset IgA vasculitis in southern Sweden 2024 ·RMD Open ·(unknown), (unknown), Mårten Segelmark, Jacob Sode, David Jayne, Aladdin J Mohammad	1
2	Validation of IgA nephropathy diagnosis in the Swedish Renal Registry 2024 ·BMC Nephrology ·(unknown), Mårten Segelmark, Jonas F. Ludvigsson, Louise Emilsson	2
3	Data-driven subclassification of ANCA-associated vasculitis: model-based clustering of a federated international cohort 2024 ·The Lancet Rheumatology ·(unknown), Arthur White, Louis J. M. Aslett, Zdenka Hrušková, Peter Lamprecht, Jacek Musiał, (unknown), (unknown), Declan O’Sullivan, Xavier Puéchal, (unknown), Mårten Segelmark, Benjamin Terrier, Vladimı́r Tesař, (unknown), Augusto Vaglio, Krzysztof Wójcik, Mark A. Little, Aladdin J Mohammad, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	8
4	The HLA region in ANCA-associated vasculitis: characterisation of genetic associations in a Scandinavian patient population 2024 ·RMD Open ·Christian Lundtoft, Ann Knight, Jennifer R. S. Meadows, Åsa Karlsson, Solbritt Rantapää‐Dahlqvist, Ewa Berglin, Øyvind Palm, Hilde Haukeland, Iva Gunnarsson, Annette Bruchfeld, Mårten Segelmark, Sophie Ohlsson, Aladdin J Mohammad, Per Eriksson, Peter Söderkvist, Lars Rönnblom, Roald Omdal, Roland Jonsson, Kerstin Lindblad‐Toh, Johanna Dahlqvist	2
5	Primary glomerular diseases and long‐term adverse health outcomes: A nationwide cohort study 2024 ·Journal of Internal Medicine ·Anne‐Laure Faucon, (unknown), (unknown), Julia Wijkström, Sigrid Lundberg, Rino Bellocco, Mårten Segelmark, Marie Evans, Juan Jesús Carrero	8
6	No impact of helminth coinfection in patients with smear positive tuberculosis on immunoglobulin levels using a novel method measuring Mycobacterium tuberculosis-specific antibodies 2023 ·Allergy Asthma and Clinical Immunology ·(unknown), (unknown), (unknown), (unknown), Thomas Schön, Mårten Segelmark, Olle Stendahl, Robert H. Gilman, Robert Blomgran	0
7	#5414 CLINICAL UTILITY OF SEROLOGICAL TEST AT TIME OF BIOPSY 2023 ·Nephrology Dialysis Transplantation ·Mårten Segelmark, Maria Weiner, Björn Peters	1
8	Stable incidence but increase in prevalence of ANCA-associated vasculitis in southern Sweden: a 23-year study 2023 ·RMD Open ·(unknown), Mårten Segelmark, Martin Englund, Aladdin J Mohammad	17
9	Time-averaged concentration estimation of uraemic toxins with different removal kinetics: a novel approach based on intradialytic spent dialysate measurements 2022 ·Clinical Kidney Journal ·(unknown), Annika Adoberg, (unknown), Annemieke Dhondt, Anders Fernström, Ivo Fridolin, Griet Glorieux, Emilio González‐Parra, (unknown), Liisi Leis, Merike Luman, María Vanessa Pérez-Gómez, Kristjan Pilt, (unknown), Mårten Segelmark, Fredrik Uhlin, Alberto Ortíz	1
10	Fewer hospitalizations and prolonged technique survival with home hemodialysis– a matched cohort study from the Swedish Renal Registry 2019 ·BMC Nephrology ·Helena Rydell, Kerstin Ivarsson, Martin Almquist, Naomi Clyne, Mårten Segelmark	14
11	Effect of Treatment on Damage and Hospitalization in Elderly Patients with Microscopic Polyangiitis and Granulomatosis with Polyangiitis 2019 ·The Journal of Rheumatology ·Maria Weiner, (unknown), Aladdin J Mohammad, Zdenka Hrušková, Anisha Tanna, P. Sharp, Amy Kang, Annette Bruchfeld, Daina Selga, (unknown), Kerstin Westman, Per Eriksson, Lorraine Harper, Charles D. Pusey, Vladimı́r Tesař, Alan D. Salama, Mårten Segelmark	9
12	Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis breakdown → 2017 ·Journal of the American Society of Nephrology ·David Jayne, Annette Bruchfeld, Lorraine Harper, Matthias Schaier, Michael Venning, Patrick Hamilton, Volker Burst, Franziska Grundmann, Michel Jadoul, István Szombati, Vladimı́r Tesař, Mårten Segelmark, Antonia Potarca, Thomas J. Schall, Pirow Bekker, (unknown)	420
13	WS7_1 Organ Damage and Hospitalization in Elderly Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis 2017 ·Lara D. Veeken ·Maria Weiner, (unknown), Aladdin J Mohammad, Zdenka Hrušková, Anisha Tanna, P. Sharp, Amy Kang, Annette Bruchfeld, Daina Selga, (unknown), Kerstin Westman, Per Eriksson, Lorraine Harper, Charles D. Pusey, Vladimı́r Tesař, Alan D. Salama, Mårten Segelmark	11
14	Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial 2015 ·Annals of the Rheumatic Diseases ·Rachel Jones, Shunsuke Furuta, Jan Willem Cohen Tervaert, Thomas Häuser, Raashid Luqmani, Matthew D. Morgan, Chen Au Peh, Caroline O.S. Savage, Mårten Segelmark, Vladimı́r Tesař, Pieter van Paassen, Michael Walsh, Kerstin Westman, David Jayne	185
15	Glomerular filtration rate (GFR) during and after STEMI: a single-centre, methodological study comparing estimated and measured GFR 2015 ·BMJ Open ·Dimitrios Venetsanos, Joakim Alfredsson, Mårten Segelmark, Eva Swahn, Sofia Sederholm Lawesson	8
16	A Candidate Gene Approach to ANCA-Associated Vasculitis Reveals Links to the C3 and CTLA-4 Genes but not to the IL1-Ra And Fcγ-RIIa Genes 2013 ·Kidney & Blood Pressure Research ·Ulf Persson, Birgitta Gullstrand, Åsa Pettersson, Gunnar Sturfelt, Lennart Truedsson, Mårten Segelmark	15
17	Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS 2009 ·Apmis ·(unknown), (unknown), Thomas Häuser, Raashid Luqmani, Chen Au Peh, Caroline O.S. Savage, Mårten Segelmark, Vladimı́r Tesař, Pieter van Paassen, (unknown), (unknown), Kerstin Westman, David Jayne	7
18	Capture ELISA for PR3-ANCA is superior to detect and predict relapses of systemic vasculitis compared with direct ELISA 2009 ·Apmis ·Daina Selga, Mårten Segelmark	1
19	Studies of mechanisms underlying the prolonged neutrophil survival in ANCA-associated systemic vasculitis 2009 ·Apmis ·(unknown), Lena Gunnarsson, Anders Bengtsson, Pierre Geborek, Mårten Segelmark, Thomas Hellmark	1
20	Screening for ANCA: Is indirect immunofluorescence the method of choice 1995 ·Clinical & Experimental Immunology ·Mårten Segelmark	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact